Approval of a new depression drug, stellar phase III data for both a schizophrenia therapy and an Alzheimer’s disease candidate, as well as an accelerated approval filing for a Duchenne muscular dystrophy gene therapy, are all reasons that BioWorld’s Neurological Diseases Index climbed from a negative position throughout much of 2022 to its 11% above-water mark as of Oct. 20.
The value of med-tech mergers and acquisitions, as well as deals, fell in the third quarter, although 2022 remains a standout year. M&As are at a five-year high, while deals are second only to 2019, in terms of overall value during the first three quarters. The volume of M&As are behind 2021, but deal volume this year remains on top.